B. Mookerjee

A. Ferber, R. Korngold, N. Flomenberg, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.

R. Korngold, N. Flomenberg, B. Mookerjee, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials

A. Hauschild, D. Schadendorf, P. Ascierto, 2021 .

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

M. Gore, P. Mulders, E. Porfiri, 2009 .

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Treatment of adenovirus disease in stem cell transplant recipients with cidofovir.

S. Dessain, A. Ferber, N. Flomenberg, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Purification of Melanoma Reactive T Cell by Using a Monocyte-based Solid Phase T-cell Selection System for Adoptive Therapy

B. Mookerjee, Jongming Li, J. Wagner, 2008, Journal of immunotherapy.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Generation of BKV-Specific T Cells for Adoptive Therapy against BKV Nephropathy

B. Mookerjee, Priya Singh, J. Wagner, 2008 .

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

M. Cazzola, T. Barbui, H. Kantarjian, 2013, Cancer.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

P. Wen, J. Schellens, J. Soria, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2017, The New England journal of medicine.

Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study.

C. Pratilas, B. Geoerger, J. Whitlock, 2018 .

LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB

B. Geoerger, C. Moertel, D. Hargrave, 2018, Neuro-Oncology.

Biological significance and molecular mechanisms of p53-induced apoptosis

B. Mookerjee, A. Bedi, 2004, Apoptosis.

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

G. Semenza, Z. Bhujwalla, L. Dillehay, 2000, Genes & development.

Overcoming drug resistance: targeting more than one site.

J. Karp, B. Mookerjee, 2002, Leukemia research.

p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300.

W. El-Deiry, A. Giordano, R. Ravi, 1998, Cancer research.

A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing.

T. Hyslop, N. Flomenberg, B. Mookerjee, 2011, Blood.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Ying Zhang, Jean-Jacques Grob, Keith T Flaherty, 2017, The Lancet. Oncology.

An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

H. Groen, J. Rigas, S. Novello, 2016 .

Adenovirus DNA polymerase is recognized by human CD8+ T cells.

N. Flomenberg, B. Mookerjee, A. Joshi, 2009, The Journal of general virology.

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB

C. Gélinas, R. Ravi, G. Bedi, 2001, Nature Cell Biology.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The Lancet. Oncology.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Jeffrey Weber, Keith T Flaherty, Zeynep Eroglu, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Dirk Schadendorf, Axel Hauschild, Antoni Ribas, 2019, European journal of cancer.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

J. Infante, H. Arkenau, M. Gordon, 2018, British journal of clinical pharmacology.

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.

K. King, J. Legos, Diptee A. Kulkarni, 2016, Pharmacogenomics.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2019, The Lancet. Oncology.

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

J. Blay, Z. Wainberg, F. Ravandi, 2018, Blood.

Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC).

P. Wen, J. Schellens, J. Soria, 2017 .

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

J. Utikal, D. Schadendorf, K. Flaherty, 2019, European journal of cancer.

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

G. Tricot, R. Fenton, B. Mookerjee, 2002, Bone Marrow Transplantation.

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.

R. Dummer, J. Larkin, G. Long, 2018 .

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2017, European journal of cancer.

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).

K. Flaherty, Douglas B. Johnson, S. Patel, 2017 .

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy.

N. Flomenberg, B. Mookerjee, J. Wagner, 2007, Journal of immunological methods.

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

B. Halmos, L. Paz-Ares, B. Cho, 2021, Annals of Oncology.

Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)

H. Groen, D. Planchard, J. Mazières, 2017 .

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC).

J. Schellens, A. Italiano, A. Boran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma.

P. Ascierto, N. Ibrahim, A. Ribas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

M. Cazzola, T. Barbui, H. Kantarjian, 2012 .

COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).

K. Flaherty, A. Arance, J. Grob, 2017 .

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG)

P. Wen, M. Campone, A. Boran, 2018, Neuro-Oncology.

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Network Boston.

Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i

D. Schadendorf, P. Ascierto, R. Dummer, 2018, Clinical Trials.

Activity of single-agent melphalan 220–300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma

D. Howard, D. Reece, A. Rapoport, 2004, Bone Marrow Transplantation.

Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer.

S. Kopetz, D. Cunningham, H. Tran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

R. Snyder, B. Mookerjee, M. Audeh, 2013, Investigational New Drugs.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.

Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600–mutant tumors.

J. Infante, H. Arkenau, M. Gordon, 2016 .

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.

B. Halmos, D. Demanse, B. Mookerjee, 2024, Lung cancer.

Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study.

R. Snyder, B. Mookerjee, M. Audeh, 2009 .